LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Bio-Techne Corp

Cerrado

SectorSalud

53.01 3.07

Resumen

Variación precio

24h

Actual

Mínimo

51.53

Máximo

53.25

Métricas clave

By Trading Economics

Ingresos

-40M

-18M

Ventas

783K

317M

P/B

Media del Sector

112.217

35.293

BPA

0.53

Rentabilidad por dividendo

0.62

Margen de beneficio

-5.577

Empleados

3,100

EBITDA

-61M

6.4M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+28.11% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.62%

3.07%

Próximas Ganancias

29 oct 2025

Fecha Próximo Dividendo

21 nov 2025

Próxima Fecha de Ex Dividendo

10 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-861M

8B

Apertura anterior

49.94

Cierre anterior

53.01

Noticias sobre sentimiento de mercado

By Acuity

27%

73%

69 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Bio-Techne Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 sept 2025, 23:56 UTC

Acciones populares

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 sept 2025, 22:01 UTC

Principales Movimientos del Mercado

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 sept 2025, 20:51 UTC

Adquisiciones, fusiones, absorciones

UPS Terminates Plan to Buy Estafeta

18 sept 2025, 20:31 UTC

Ganancias

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 sept 2025, 20:26 UTC

Ganancias

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 sept 2025, 23:43 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 sept 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 sept 2025, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

18 sept 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 sept 2025, 23:31 UTC

Charlas de Mercado

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 sept 2025, 22:03 UTC

Ganancias

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 sept 2025, 22:01 UTC

Ganancias

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 sept 2025, 21:56 UTC

Ganancias

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 sept 2025, 21:54 UTC

Ganancias

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 sept 2025, 21:48 UTC

Ganancias

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 sept 2025, 21:47 UTC

Ganancias

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 sept 2025, 21:17 UTC

Ganancias

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 sept 2025, 21:07 UTC

Ganancias

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sept 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

18 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 sept 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

18 sept 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

18 sept 2025, 20:22 UTC

Adquisiciones, fusiones, absorciones

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 sept 2025, 20:22 UTC

Adquisiciones, fusiones, absorciones

United Parcel Service Terminates Plan to Buy Estafeta

18 sept 2025, 20:20 UTC

Adquisiciones, fusiones, absorciones

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 sept 2025, 20:18 UTC

Ganancias

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 sept 2025, 20:18 UTC

Ganancias

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 sept 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

18 sept 2025, 20:07 UTC

Ganancias

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sept 2025, 20:03 UTC

Ganancias

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Comparación entre iguales

Cambio de precio

Bio-Techne Corp Esperado

Precio Objetivo

By TipRanks

28.11% repunte

Estimación a 12 meses

Media 66 USD  28.11%

Máximo 75 USD

Mínimo 53 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bio-Techne Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

10

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

49.67 / 50.24Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

69 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat